Skip to content

The Effect of Adiponectin-Leptin Ratio on Weight Loss in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity

The Effect of Adiponectin-Leptin Ratio on Weight Loss in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07564973
Enrollment
78
Registered
2026-05-04
Start date
2025-01-01
Completion date
2026-04-27
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity Requiring Bariatric Surgery

Keywords

morbid obesity, bariatric surgery, sleeve gastrectomy, Adiponectin, Leptin, Adiponectin-Leptin Ratio

Brief summary

The study aims to find out if a specific blood test, measuring the balance between two hormones (adiponectin and leptin), can predict how much weight a person might lose after sleeve gastrectomy, a surgery for obesity. The investigators want to see if this hormone ratio can help identify who will benefit most from the surgery. If the investigators find that people with a low hormone ratio are less likely to lose weight after surgery, doctors can guide them toward other weight-loss options, like lifestyle changes or different treatments, instead of surgery. This way, patients can get the care that's best for them.

Detailed description

The subject of the research is to investigate whether preoperative adiponectin-leptin ratios are predictive of weight loss in patients undergoing sleeve gastrectomy for morbid obesity. If the study finds the adiponectin-leptin ratio to be a significant predictor of weight loss, individuals with a low preoperative ratio, which are expected to lose less weight following surgery, can be redirected to more suitable treatment options other than sleeve gastrectomy. This will allow patients less likely to benefit from surgery to be guided toward conservative approaches.

Interventions

PROCEDURELaparoscopic Sleeve Gastrectomy

Laparoscopic Sleeve Gastrectomy

Sponsors

Sercan YUKSEL, MD
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 to 75 * International Classification of Diseases (ICD) code E66 diagnosis (obesity) * Patients who have given consent for sleeve gastrectomy * Patients who are suitable for general anesthesia

Exclusion criteria

* Patients who did not give consent to be included in the study * Patients who are scheduled for surgery other than sleeve gastrectomy

Design outcomes

Primary

MeasureTime frame
Change in body mass index at 8 months8 months after surgery

Secondary

MeasureTime frame
Change in lipid profile at 8 months8 months after surgery

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026